Patricia L. Lugar

ORCID: 0000-0002-7725-7424
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Immunodeficiency and Autoimmune Disorders
  • Drug-Induced Adverse Reactions
  • Lymphoma Diagnosis and Treatment
  • Immune Cell Function and Interaction
  • Cystic Fibrosis Research Advances
  • Pharmacovigilance and Adverse Drug Reactions
  • Urticaria and Related Conditions
  • Blood groups and transfusion
  • Contact Dermatitis and Allergies
  • Chronic Lymphocytic Leukemia Research
  • Pneumocystis jirovecii pneumonia detection and treatment
  • Autoimmune Bullous Skin Diseases
  • Blood disorders and treatments
  • Food Allergy and Anaphylaxis Research
  • Antimicrobial Resistance in Staphylococcus
  • Mast cells and histamine
  • Eosinophilic Disorders and Syndromes
  • T-cell and B-cell Immunology
  • Cancer-related molecular mechanisms research
  • Viral-associated cancers and disorders
  • Coagulation, Bradykinin, Polyphosphates, and Angioedema
  • MicroRNA in disease regulation
  • RNA Interference and Gene Delivery
  • Platelet Disorders and Treatments
  • Allergic Rhinitis and Sensitization

Duke Medical Center
2014-2024

Duke University
2008-2023

Duke University Hospital
2013-2022

Asthma and Allergy Specialists
2019

Duke University Health System
2017-2018

Pulmonary and Allergy Associates
2017-2018

George Washington University
2017

National Institutes of Health
2012

National Institute of Arthritis and Musculoskeletal and Skin Diseases
2008-2009

United States Department of Health and Human Services
2006

Diffuse large B-cell lymphoma (DLBCL) is the most common form of in adults. The disease exhibits a striking heterogeneity gene expression profiles and clinical outcomes, but its genetic causes remain to be fully defined. Through whole genome exome sequencing, we characterized diversity DLBCL. In all, sequenced 73 DLBCL primary tumors (34 with matched normal DNA). Separately, exomes 21 cell lines. We identified 322 cancer genes that were recurrently mutated DLBCLs. recurrent mutations...

10.1073/pnas.1205299110 article EN Proceedings of the National Academy of Sciences 2013-01-04

We evaluated the overall and site-specific incidence of cancer in subjects with primary immunodeficiency diseases (PIDD) enrolled United States Immune Deficiency Network (USIDNET) registry compared age-adjusted Surveillance, Epidemiology End Results Program (SEER) database.

10.1016/j.jaci.2017.05.024 article EN publisher-specific-oa Journal of Allergy and Clinical Immunology 2017-06-10

Importance Fewer than 5% of patients labeled with a penicillin allergy are truly allergic. The standard care to remove the label in adults is specialized testing involving prick and intradermal skin followed by an oral challenge penicillin. Skin resource intensive, limits practice specialist-trained physicians, restricts global population who could undergo delabeling. Objective To determine whether direct noninferior low-risk allergy. Design, Setting, Participants This parallel, 2-arm,...

10.1001/jamainternmed.2023.2986 article EN JAMA Internal Medicine 2023-07-17

Interferon (IFN) consensus sequence-binding protein/IFN regulatory factor 8 (IRF8) is a transcription that regulates the differentiation and function of macrophages, granulocytes, dendritic cells through activation or repression target genes. Although IRF8 also expressed in lymphocytes, its roles B cell T maturation are ill defined, few transcriptional targets known. Gene expression profiling human tonsillar mouse lymphomas showed transcripts were at highest levels centroblasts, either from...

10.1084/jem.20051450 article EN The Journal of Experimental Medicine 2005-12-27

Enteropathy-associated T cell lymphoma (EATL) is a lethal, and the most common, neoplastic complication of celiac disease. Here, we defined genetic landscape EATL through whole-exome sequencing 69 tumors. SETD2 was frequently silenced gene in (32% cases). The JAK-STAT pathway mutated pathway, with frequent mutations STAT5B as well JAK1, JAK3, STAT3, SOCS1. We also identified KRAS, TP53, TERT. Type I type II (monomorphic epitheliotropic intestinal lymphoma) had highly overlapping alterations...

10.1084/jem.20160894 article EN cc-by-nc-sa The Journal of Experimental Medicine 2017-04-19

Systemic lupus erythematosus (SLE) is a generalized autoimmune disease characterized by abnormal B cell activation and the occurrence of increased frequencies circulating plasma cells (PC). The molecular characteristics nature PC in SLE have not been completely characterized. Microarray analysis gene expression was used to characterize subjects with active SLE. Flow cytometry sort comparator populations from blood, normal blood tonsil. profiles sorted were then compared. exhibited similar...

10.1371/journal.pone.0044362 article EN cc-by PLoS ONE 2012-09-21

Penicillin allergies are frequently mislabeled, which may contribute to use of less-preferred alternative antibiotics.To evaluate a pharmacist-led allergy assessment program's association with antimicrobial and clinical outcomes.A program was launched in 2 phases (June 1, 2015, November 2, 2016) at single-center tertiary referral hospital. The longitudinal cross-sectional study included all period adult admissions; hospitalwide outcomes were assessed by segmented regression. Individual...

10.1001/jamanetworkopen.2021.9820 article EN cc-by-nc-nd JAMA Network Open 2021-05-13

Purpose: Use of the T cell-dependent neoantigen bacteriophage ΦX 174 has been described since 1960s as a method to assess specific antibody response in patients with primary immunodeficiencies. We reviewed cohort at Duke University Medical Center (DUMC) who received immunization and report clinical utility safety immunization, well patient characteristics. Methods: A retrospective chart review was performed all Immunology Clinic (pediatric adult) immunizations bacteriophage, from 1976-2012....

10.3389/fimmu.2014.00410 article EN cc-by Frontiers in Immunology 2014-08-29

Aim: A novel, Investigational Wearable Infusor (IWI) was evaluated in a randomized, controlled, crossover, open-label study to determine if its delivery of subcutaneous immunoglobulin (IgPro20) achieved comparable area under the concentration-time curve (AUC) for G (IgG) versus Crono S-PID-50 infusion pump (CP). EudraCT: 2016-003798-16. Materials & methods: Patients with primary immunodeficiency (PID) were randomized receive IgPro20 Sequence 1 (CP/IWI) or 2 (IWI/CP). The end point AUC IgG...

10.2217/imt-2022-0097 article EN cc-by-nc-nd Immunotherapy 2022-09-21

A 79-year-old woman with macular degeneration was referred to the Allergy/Immunology clinic for evaluation of a potential allergy anti-vascular endothelial growth factor (anti-VEGF) treatments. The patient developed urticaria and eyelid swelling immediately following retinal injection aflibercept, which she had previously tolerated. She allergic reactions ranibizumab bevacizumab injections. Injections anti-VEGF treatments were discontinued given concern progression patient's disease.To...

10.1177/2152656718763385 article EN cc-by-nc Allergy & Rhinology 2018-01-01

Abstract Purpose To evaluate the safety and tolerability of IgPro20 manual push (also known as rapid push) infusions at flow rates 0.5–2.0 mL/min. Methods Patients with primary immunodeficiency (PID) previous experience administering (Hizentra ® , CSL Behring, King Prussia, PA, USA) were enrolled in Hizentra Label Optimization (HILO) study (NCT03033745) assigned to Pump-assisted Volume Cohort, Flow Rate or Manual Push Cohort; this report describes latter. administered via 0.5, 1.0, 2.0...

10.1007/s10875-020-00876-6 article EN cc-by Journal of Clinical Immunology 2020-10-06

Inspired by the ABIM Foundation's Choosing Wisely® campaign, "Things We Do for No Reason™" (TWDFNR) series reviews practices that have become common parts of hospital care but may provide little value to our patients. Practices reviewed in TWDFNR do not represent "black and white" conclusions or clinical practice standards are meant as a starting place research active discussions among hospitalists invite you be part discussion.

10.12788/jhm.3170 article EN Journal of Hospital Medicine 2019-03-20
Coming Soon ...